EP4090686A4 - Pro-antibody that reduces off-target toxicity - Google Patents

Pro-antibody that reduces off-target toxicity

Info

Publication number
EP4090686A4
EP4090686A4 EP21741991.0A EP21741991A EP4090686A4 EP 4090686 A4 EP4090686 A4 EP 4090686A4 EP 21741991 A EP21741991 A EP 21741991A EP 4090686 A4 EP4090686 A4 EP 4090686A4
Authority
EP
European Patent Office
Prior art keywords
pro
antibody
reduces
target toxicity
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21741991.0A
Other languages
German (de)
French (fr)
Other versions
EP4090686A2 (en
Inventor
Kuo-Fu Tseng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Targeting Inc
Original Assignee
Immune Targeting Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Inc filed Critical Immune Targeting Inc
Priority claimed from PCT/US2021/013688 external-priority patent/WO2021146590A2/en
Publication of EP4090686A2 publication Critical patent/EP4090686A2/en
Publication of EP4090686A4 publication Critical patent/EP4090686A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
EP21741991.0A 2020-01-17 2021-01-15 Pro-antibody that reduces off-target toxicity Pending EP4090686A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062962555P 2020-01-17 2020-01-17
PCT/US2021/013688 WO2021146590A2 (en) 2020-01-17 2021-01-15 Pro-antibody that reduces off-target toxicity

Publications (2)

Publication Number Publication Date
EP4090686A2 EP4090686A2 (en) 2022-11-23
EP4090686A4 true EP4090686A4 (en) 2024-03-27

Family

ID=82906067

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21741991.0A Pending EP4090686A4 (en) 2020-01-17 2021-01-15 Pro-antibody that reduces off-target toxicity

Country Status (2)

Country Link
EP (1) EP4090686A4 (en)
CN (1) CN114945597A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use
WO2019051102A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33492A (en) * 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
UA117901C2 (en) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
US11147852B2 (en) * 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
MX2014013041A (en) * 2012-04-27 2015-03-19 Cytomx Therapeutics Inc Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof.
US20150087810A1 (en) * 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3288981A1 (en) * 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
CA2986604A1 (en) * 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
US11466093B2 (en) * 2015-07-27 2022-10-11 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
EP3465221B1 (en) * 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3592775A1 (en) * 2017-03-09 2020-01-15 CytomX Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
US11364303B2 (en) * 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
EP4023230A4 (en) * 2019-06-05 2023-11-15 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule
EP4126955A1 (en) * 2020-03-26 2023-02-08 Aetio Biotherapy, Inc. Bi-specific fusion proteins for depletion of regulatory t cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use
WO2019051102A2 (en) * 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANG SHANSHAN ET AL: "LegoBody: facile generation of bispecific and multi-specific antibodies", BIORXIV, 27 December 2019 (2019-12-27), XP093129094, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2019.12.25.888586v1.full.pdf> [retrieved on 20240208], DOI: 10.1101/2019.12.25.888586 *

Also Published As

Publication number Publication date
CN114945597A (en) 2022-08-26
EP4090686A2 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
CA208524S (en) Soundbar
CA199411S (en) Handshower
CA196956S (en) Onesie
EP4090686A4 (en) Pro-antibody that reduces off-target toxicity
CA198107S (en) Protractor-ruler
GB2591307B (en) Biasing Circuitry
CA212416S (en) Aéronef
CA212654S (en) Velomobile
CA208693S (en) Arrowhead
CA208692S (en) Arrowhead
CA208694S (en) Arrowhead
DK4001080T3 (en) Lasthjul
CA207518S (en) Smartglasses
CA207517S (en) Smartglasses
CA207519S (en) Smartglasses
CA207516S (en) Smartglasses
CA207311S (en) Handleset
CA206631S (en) Mandoline
CA204910S (en) Volvelle
CA204810S (en) Playard
CA204263S (en) Brushguard
CA204055S (en) Spiralizer
CA201360S (en) Débardeur
CA200872S (en) Nighstand
CA200597S (en) Hoodie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNE TARGETING INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20240227

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/58 20060101ALI20240221BHEP

Ipc: A61P 37/02 20060101ALI20240221BHEP

Ipc: A61P 17/06 20060101ALI20240221BHEP

Ipc: A61P 35/00 20060101ALI20240221BHEP

Ipc: C07K 16/30 20060101AFI20240221BHEP